From Beginning to End: The Importance of Evidence-Based Policymaking in Vaccination Mandates

Eyler J. M. , “Smallpox in History: The Birth, Death, and Impact of a Dread Disease,” Journal of Lab Clinical Medicine 142, no. 4 (2003): 216–220.

Law S. , “Human Papillomavirus Vaccination, Private Choice, and Public Law,” University of California Davis Law Review 41, no. 5 (2008): 1731–1772.

Craig A. , “New Adolescent Vaccines: Legal and Legislative Issues,” Journal of Law, Medicine & Ethics 35, no. 4, Supp. (2007): 106–111.

National Conference of State Legislatures, States with Religious and Philosophical Exemptions from School Immunization Requirements (December 2012), available at <http://www.ncsl.org/research/health/school-immunization-exemption-state-laws.aspx> (last visited January 29, 2015).

197 U.S. 11 (1905).

See Law , supra note 2.

Andrus J. K. , “A Model for Enhancing Evidence-Based Capacity to Make Informed Policy Decisions on the Introduction of New Vaccines in the Americas: Paho's Provac Initiative,” Public Health Reports 122, no. 6 (2007): 811–816.

See Law , supra note 2.

Jacobson , 197 U.S. 11 at 27, 39.

Lucas A. , “Mandated Human Papillomavrius Vaccination: An Overextension of Jacobson v. Massachusetts,” Thomas M. Cooley Journal of Practical and Clinical Law 10, no. 2 (2008): 253–283.

Law , supra note 2.

National Conference of State Legislatures, HPV Vaccine Policies, available at <http://www.ncsl.org/research/health/hpvvaccine-state-legislation-and-statutes.aspx> (last visited January 29, 2015).

D.C. Code § 7–1651.04(b)(1)(B)(iii)(2008); Va. Code Ann. § 32.1–46(D)(3)(2008); Presley M. K. , “The Constitutionality of an HPV Mandate and Its Implications for the Minor Patient,” American Bar Association Health Lawyer 25, no. 2 (2012): 1–7, at 1.

Cherkin M. , “Three Shots in the Arm: The HPV Vaccine and Inclusive Health Policy,” University of Pennsylvania Journal of Law & Social Change 15, no. 3 (2012): 475–499.

Markowitz L. E. , “Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP),” Morbidity and Mortality Weekly Report 56, no. RR02 (2007): 1–24; Dunne E. F. , “Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males – Advisory Committee on Immunization Practices (ACIP), 2011,” Morbidity and Mortality Weekly Report 60, no. 50 (2011): 1705–1708.

See Lucas , supra note 12.

Stokley S. , “Human Papillomavirus Vaccination Coverage among Adolescents, 2007–2013, and Postlicensure Vaccine Safety Monitoring, 2006–2014 – United States,” Morbidity and Mortality Weekly Report 63, no. 29 (2014): 620–624.

Cal. Health & Safety Code § 120365(b); Or. Rev. Stat. § 433.267(B); Wash. Admin. Code § 28A.210.090.

H.B. 14–1288, 69th Gen. Assemb., Second Reg. Sess. (Colo. 2014).

For example, Omer S. B. (letter to the editor), “Vaccination Policies and Rates of Exemption from Immunization, 2005–2011,” New England Journal of Medicine 367, no. 12 (2012): 1170–1171; Yang Y. T. Debold V. , “A Longitudinal Analysis of the Effect of Nonmedical Exemption Law and Vaccine Uptake on Vaccine-Targeted Disease Rates,” American Journal of Public Health 104, no. 2 (2014): 371–377.

For example, Phillips v. New York, No. 14–2156-cv (2nd Cir. filed June 10, 2014).